Article by Justin L Scharton, Independent Researcher
​
Article written on February 5, 2025
​
Modern Seizure Management: Exploring Cannabinoids, Terpenes, and New Pharmacological Targets
​
Disclaimer: The information shared here includes information about my personal experience and current research. It is not intended to replace professional medical advice. Always consult a qualified healthcare provider before making changes to your treatment plan or trying any new therapy.
​
There are several different types of seizures, and some different physiology between them. Some seizure types are caused by overactive neurons. Other seizure types can be caused from extreme vasodilation, not allowing proper blood flow to the brain. In this section, we will go over:
Cannabinoids for Seizure Control: Reviewing how different cannabis compounds may influence seizure thresholds.
Potential Cannabinoid and Terpene Combinations: Exploring theoretical mixes that may warrant further research.
Terpenes and Their Influence on Seizures: Examining how these aromatic plant compounds can modulate neuronal and vascular processes, how they affect different seizure types, and possible interactions with a vagus nerve stimulator.
Adenosine A2A receptor: Seizure reduction with Humulene and its role as an adenosine A2A modulator, and the possible roles with seizure control with adenosine A2A agonists, antagonists, and modulators.
Medications Commonly Prescribed for Debilitating Seizures: An overview of established pharmaceutical approaches to help us understand pharmacological targets.
Febrile Seizure Caution: Considering the roles of TRPV3 and TRPM8 activation, and why they may matter in fever-related seizure types.
​
​
​
​
Cannabinoids for seizure control
CBD, CBC, and CBN are effective at reducing seizures at low doses. (13F) THC and THCA has shown to reduce some types of seizures. A mouse with Dravet did show an increase in seizures with THC and THCA. THCA has a hard time entering brain cells, unlike THC. (14F) Using THC or THCA is going to be an individual response, with some people getting less seizures, while other types might have their seizures worsened.
CBDV has anti-seizure properties, and was used in a Phase 2a placebo-controlled study for focal seizure but did not reach the primary endpoints back in February 2018. There is not much more known about the mechanism of action. (81B)
​
​
​
​
Possible Cannabinoid and Terpene Combinations Worth
Researching for Seizure Control
1. Seizure Types Caused by Vasodilation Worsened by THC
Possible Cannabinoid Combination: Cannabidiol (CBD), cannabichromene (CBC), and cannabinol (CBN). Each of these cannabinoids has shown some seizure-reducing effects in various models. (13F)
​
Possible Helpful Terpenes: Humulene, Terpineol and Eucalyptol
​
Humulene: May help maintain blood flow to the brain by modulating the adenosine A2A receptor, which is involved with vascular tone regulation. (6D,17F)
​
Terpineol: Could help reduce excessive brain activity and increase blood pressure due to its anticholinergic properties. (11D,47F,48F)
​
Eucalyptol: TRPM8 agonist which could increase blood flow to the brain by causing peripheral vasoconstriction. (33D,19F,49F)
Avoid: excessive TRPV3 activation which will cause vasodilation. (42A,43A)
​
​
​
2. Seizure Types Caused by Vasodilation Lessened by THC
Possible Cannabinoid Combination: THC, THCA, CBD, CBC, and CBN. (13F,51F) A wider range of cannabinoids could reduce the side effects of only taking large doses of one, and help reduce seizures through their anti-inflammatory or other effects.
​
Possible Helpful Terpenes: Humulene, Terpineol and Eucalyptol
Humulene: May help maintain blood flow to the brain by modulating the adenosine A2A receptor, which is involved with vascular tone regulation.(6D,17F)
​
Terpineol: Could help reduce excessive brain activity and increase blood pressure due to its anticholinergic properties. (11D,47F,48F)
​
Eucalyptol: TRPM8 agonist which could increase blood flow to the brain by causing peripheral vasoconstriction. (33D,19F,49F)
Avoid: excessive TRPV3 activation which will cause vasodilation. (42A,43A)
​
​
Personal Example
Lemon Walker (THC) Infused Chocolate: Dominant terpenes are limonene and terpineol. Strain side effects include dry mouth and eyes.
​
White Walker (THC) in MCT Oil: Dominant terpenes are humulene and terpineol. Strain side effects include dry mouth and eyes, as well as a hungry and shaky feeling.
​
Water-Cured CBD Lemon Skunk in MCT oil: Terpenes largely removed, some CBN present due to trichome oxidation. Strain side effects are minimal for water-cured, but original lemon skunk terpenes can be nauseating.
I do use about twice as much THC as CBD. Individual responses will vary, and each person would need to try out different combinations to see what works for them. The strains I have are what I have available to me, and what grows well taking a clone from a clone year after year. Another combination I would like to try is the original White Widow, or CBD White Widow along with Lemon Walker. The original White Widow has humulene, caryophyllene, a-pinene, terpineol, and myrcene; which might be a little less sedating than White Walker.
​
​
​
3. Seizures Caused by Brain Overactivity
Possible Cannabinoid Combination: Non-Psychoactive CBD, CBC, CBN — Each may help reduce excessive neuronal firing. (13F) CBN has sedative properties, potentially calming overactive brain activity. THC tends to heighten excitatory activity. THCA is relatively unstable, possibly converting into THC over time.
Potentially Helpful Terpenes: Terpineol and linalool - Both are often regarded as sedative or relaxing terpenes; they may reduce excitatory signaling.
Avoid: Acetylcholinesterase inhibitors (e.g., α-pinene in high doses) if overactivity is a concern, as they may increase brain excitability.
Terpenes that are acetylcholinesterase inhibitors are: limonene, a-pinene, beta-caryophyllene, beta-caryophyllene oxide, humulene, and delta 3 carene. (37E,52C)
​
​
​
Notes and Considerations
Individual Responses: The effect of specific cannabinoids and terpenes can vary dramatically among individuals. Some may experience reduced seizure frequency, while others see no improvement or even a worsening of symptoms.
Research Gaps: Much of the discussion around cannabinoid-terpene synergy (entourage effect) in seizures remains preclinical or anecdotal. Rigorous clinical trials are needed.
​
Strain Variability: Cannabis strains labeled with the same name can still differ in terpene/cannabinoid profiles, known as chemotypes. Lab testing is ideal for knowing exact chemical compositions.
Medical Oversight: Anyone considering these combinations for seizure management should consult a licensed medical professional.
​
​
​
How terpenes could influence seizures
Research on how specific terpenes influence various seizure disorders is extremely limited. Much of what is here is theoretical and should not replace professional medical advice. Always consult a licensed medical professional before attempting to treat medical problems with terpenes or any other supplements.
​
​
​
Alpha-Pinene
Acetylcholinesterase Inhibition: α-Pinene is reported to inhibit acetylcholinesterase (AChE).(5C) Inhibiting AChE raises acetylcholine (ACh) levels, which can enhance parasympathetic (vagal) activity, potentially lowering heart rate. (10C)
Effects on the Brain: Because AChE inhibitors are used in certain forms of dementia to boost cholinergic signaling, (10C) α-pinene may similarly increase central cholinergic activity. This could, in theory, heighten excitatory processes in certain brain regions.
Cerebral Blood Flow: Chronic AChE inhibition can lead to increased cerebral blood flow, (15F) which might help conditions triggered or exacerbated by reduced perfusion to the brain.
Possible Interaction with Vagus nerve stimulators (VNS): May enhance parasympathetic tone and can cause bradycardia or, in rare cases, cardiac standstill.(16F) Combining VNS with any additional parasympathetic stimulation (such as α-pinene) could possibly worsen the cardiovascular risks.
​
​
Potential Seizure-Related Implications with a-pinene
Vasodilation-Induced Seizures: If a person’s seizures are linked to reduced blood flow (due to excessive vasodilation elsewhere in the body), α-pinene’s boost in parasympathetic tone and improved cerebral circulation might be beneficial.
Hyperexcitable Seizure Types: Elevated ACh in the brain could worsen seizure disorders characterized by neuronal overactivity.
Cardiovascular Caution: Using α-pinene alongside a vagus nerve stimulator may carry serious cardiovascular implications, such as profound bradycardia. Individuals with cardiac concerns or those who already use VNS should approach α-pinene (or any strong AChE inhibitor) with extreme caution.
​
​
​
Humulene
Humulene is an adenosine A2A modulator, and an acetylcholinesterase inhibitor with an IC(50)=785.3 ± 66.0. (6D,37E) When Adenosine A2A is activated by an agonist, vasodilation will occur. This receptor is also involved with vascular tone regulation.(17F) Since humulene is a modulator, it could be regulating the blood pressure, maintaining the blood flow in the body. With this type of modulation, blood pressure could be less prone to changes from outside influences like heat induced vasodilation.
Humulene is not researched for anti-seizure effects. I have found this terpene to be incredibly helpful for my seizures, which is characterized as non-epileptic. Some doctors say that it can be called convulsive syncope. The main problem is that blood pressure changes, and vasodilation will cause me to have that type of seizure. Hot showers, hot weather, or any type of external heat will cause an excessive vasodilatory response in me. Adrenaline and noradrenaline responses can also affect those seizures.
​
​
Isolated Humulene
Isolated terpenes can be dangerous, even ones extracted from food. 1 sublingual drop of isolated humulene caused me to have some severe chest pain, even if it was mixed with another strain of marijuana. I did not ever experience chest pain with humulene strains, like White Widow or strains crossed with it like Skywalker X White Widow, or Blue Dream X White Widow. Diluting the humulene (1 part) with 30 parts of myrcene made it more tolerable. It did not work as well, and had more side effects compared to using a humulene strain like White Widow.
​
​
​
Possible effects of Adenosine A2A agonists, antagonists, and modulators with
Sudden Unexpected Death in Epilepsy (SUDEP)
An A2AR agonist could worsen SUDEP risk in this model by further raising receptor activity already elevated under epileptic conditions. This can be inferred due to role of antagonists of A2A.
An A2AR antagonist (as shown by SCH58261) reduces SUDEP events, likely by dampening excessive or maladaptive NTS signaling.(18F)
An A2AR modulator might fine-tune these pathways, providing seizure- or SUDEP-preventing benefits while minimizing side effects. This needs more targeted research.
​
​
​
​
Eucalyptol and TRPM8 activation -The cold receptor
Can TRPM8 activation reduce seizures?
It is known that cold air blowing on the face while driving can increase cerebral perfusion.(19F) When I systemically activated TRPM8 through either a raw THCA Lemon Kush filled capsule, or tea made with the leaves of that plant; my seizures were gone. This did create a cold feeling throughout my whole body. Taking too much TRPM8 agonists can cause shivering. About 0.2-0.3 grams of Lemon Kush dried flowers worked well for about 4-6 hours. 1 large fan leaf soaked in hot water was enough to get a good cold effect. Eating the large leaf was too intense with the cold activation.
Most strains do not cause a cold feeling, and the decarboxylated form of Lemon Kush also did not provide the cold feeling. This could be from more TRPM8 antagonists, and TRPV agonists from the decarboxylated cannabinoids. Eucalyptol is the only known cannabis compound known to activate TRPM8 (agonist). I don’t have a lab test to see what is all in that plant.
Eucalyptol is an agonist of TRPV3 and TRPM8, and a TRPA1 antagonist,(38A,33D) which seems like they would cancel each other out. I personally feel the cold sensation from eucalyptol, but it is not known if others would feel differently with it. It is possible that the TRPM8 activation could be stronger than the TRPV3 activation, overriding the warm feeling effect of it. The antagonism of TRPA1 could also influence the vascular changes, but research is lacking on this type of information.
TRPM8 activation worked well for a few years to reduce my seizures, but I had to stop taking that after developing some minor heart problems from low phosphate caused by Keppra. After this point, I had to switch to a humulene strain (White Walker).
​
​
​
Cold can increase cerebral perfusion
A study about cold face stimulation (from a driving reflex) resulted in bradycardia, peripheral vasoconstriction, and an increase in blood pressure. Some cerebral vasoconstriction occurred, but there was an increase in cerebral perfusion.(19F)
​
​
​
Studies on weather, temperature, and humidity affecting the heart
Ventricular Tachycardia in Warmer or Higher-Pressure Conditions - A study found that older adults and women experienced more episodes of ventricular tachycardia when temperature or atmospheric pressure was higher. (20F)
Atrial Fibrillation in Cold, Dry Air - In contrast, colder, drier weather was linked to increased atrial fibrillation in elderly individuals. (21F)
​
​
​
​
Linalool
Linalool is a NMDA receptor antagonist.12F Ketamine is also a NMDA antagonist (22F) that has been used to treat super-refractory status epilepticus, (23F) and also can induce seizures in people with no seizure history. (50F) The NMDA receptor is where the ligands like glutamate which is the brain's primary excitatory neurotransmitter. (24F)
Linalool would likely be helpful with seizure types that involve neuronal overactivity, but it might not help vasodilation induced seizures.
​
What will happen with inhibiting acetylcholine with linalool along with a vagus nerve stimulator?
There is no research to show what happens with lowering acetylcholine while using a vagus nerve stimulator (VNS). It is possible that the VNS could be less effective, and also, parasympathetic side effects like bradycardia could also be reduced.
​
​
​
​
Terpineol
Terpineol is an anticholinergic. (11D) Anticholinergics can increase blood pressure and heart rate. (25F)
Side effects or toxicity of prescription anticholinergics include rapid heart rate, arrhythmias, urinary retention, blurred vision, constipation, reduced gut motility, hyperthermia, and inhibition of sweating. (35C)
Anticholinergics could reduce seizure frequency and spontaneous recurrent seizures in posttraumatic epilepsy (PTE), which occur after a traumatic brain injury. (26F) Terpineol might be helpful for seizures with increased brain activity by reducing the activity of acetylcholine. It also might help with the vasodilation type of seizures by increasing blood pressure.
​
What will happen with inhibiting acetylcholine with terpineol along with a vagus nerve stimulator?
​
Terpineol combined with a vagus nerve stimulator could be less effective at seizure reduction. It can also reduce the parasympathetic side effects like bradycardia.
​
​
​
​
Myrcene
Myrcene is a mu-opioid and alpha 2-adrenoreceptor modulator. (69C) The Mu-3 opioid receptor is responsible for vasodilation. (90A)
Some opioid medications like morphine and tramadol can induce seizures. Some individuals could get a seizure with low or high doses of those medications. This is an individual response, and myrcene does not act exactly the same as those medications. (27F)
Myrcene also modulates the adenosine A2A receptor (69C) which is involved with vascular tone regulation.(17F) This terpene is a well known Indica terpene that has been described as contributing to a “stuck sitting on the couch” type effect, AKA Couch Lock. It is possible that myrcene could worsen some seizure types. It might be helpful for people with adrenaline type disorders that contribute to certain seizure types. The vasodilation effects of myrcene are from the Mu-opioid receptor activation, and would likely override the action of modulating the alpha 2-adrenoreceptor.
​
​
​
​
Terpenes that could worsen vasodilatory induced seizures
TRPV3 agonists can cause vasodilation through triggering the release of Adenosine Triphosphate (ATP), calcitonin gene-related peptide (CGRP), nitric oxide (NO), and prostacyclin (PGI2). (42A,43A)
Terpenes that are TRPV3 agonists include: camphor, menthol, dihydrocarveol, 1,8-cineol (eucalyptol),(38A) 6-tert-butyl-m-cresol, carvacrol, dihydrocarveol, thymol, carveol, (+)-borneol, (39A) and eugenol. (36A)
Other agonists: 2-aminoethoxydiphenyl borate (2-APB),(38A) TRPV3 is activated from temperatures 22 and 40 degrees C, and an increased response at noxious temperatures greater than 39 degrees C. (40A)
Whole herbs that contain terpenes that are agonists to TRPV3: oregano, savory, clove and thyme. (41A)
​
​
​
​
Febrile Seizures Warning with TRPV3 and TRPM8 activation
There is research lacking on how receptors like TRPV3 and TRPM8 can affect seizures induced by a fever. Since TRPV3 can cause vasodilation, that could possibly reduce a fever from allowing the body heat to leave the body faster. Even though TRPV3 causes a warming sensation. The vasodilation effect could worsen seizures that are caused from the lowered blood pressure.
TRPM8 agonists like eucalyptol and menthol can cause a cooling sensation. (55A)
TRPM8 activation can cause vasoconstriction or vasodilation, depending on previous vasomotor tone. (28F) When blood vessels constrict, blood leaves the periphery and goes to central circulation. If there is peripheral vasoconstriction, it could make a fever worse by not allowing the body heat to leave effectively.
TRPV3 information is mentioned earlier on this page, in the previous section.
​
​
​
​
Medications often prescribed for debilitating seizure types
Lennox-Gastaut syndrome: Medications for Lennox-Gastaut syndrome can include valproate, clobazam, felbamate, lamotrigine, rufinamide, topiramate, and cannabidiol (CBD). (29F)
Dravet syndrome has symptoms that include spontaneous generalized tonic-clonic seizures, susceptibility to seizures induced by elevated body temperature, and elevated risk of sudden unexpected death in epilepsy. The Cav3.1 subunit of the T-type calcium channel family is abnormal in Dravet syndrome. (30F) Treating abnormal calcium channels can be tricky since that can affect blood pressure, heart rate and rhythm.
Dravet syndrome is often treated with seizure meds like oxcarbazepine, carbamazepine, phenytoin, lamotrigine, fenfluramine and cannabidiol (CBD). (31F)
Stiripentol (STP; Diacomit®) is an antiepileptic drug indicated for Dravet syndrome that has been identified as a γ-aminobutyric acid (GABAergic) positive allosteric modulator. (32F)
The medication valproate is generally considered a first-line therapy for various seizure types. Other anticonvulsant medications may include clobazam, felbamate, lamotrigine, rufinamide, topiramate, and cannabidiol. The U.S. Food and Drug Administration (FDA) approved cannabidiol (Epidiolex, derived from marijuana) for the treatment of seizures associated with Lennox-Gastaut syndrome in individuals ages 2 and older. The drug contains only a small amount of the psychoactive element in marijuana and does not induce euphoria associated with the drug. (36F)
​
​
​
​
Keppra (Levetiracetam)
Keppra (Levetiracetam) is used to partial, myoclonic, and tonic-clonic seizures. It reduces calcium-dependent vesicular neurotransmitter release from binding to the synaptic vesicle protein 2A (SV2A). (33F) Keppra inhibits presynaptic glutamate release in the dentate gyrus by reducing both AMPA- and NMDA-mediated excitatory postsynaptic currents (EPSCs). (34F)
Side effects of Keppra include low phosphate, low calcium, elevated alkaline phosphatase,(35F) sedation, fatigue, mood swings, headache, agitation, irritability, aggression, depression, memory loss, confusion, paresthesia, a decline in cognition, and increased suicide risk. (33F)
​
​
​
​
Valproic Acid
Sodium Channel Inhibition: Valproic acid (VPA) decreases the ability of neurons to fire at high frequencies by prolonging the inactivated state of voltage-gated sodium channels. (36F)
Enhancement of GABAergic Tone: VPA increases the synthesis of GABA and inhibits GABA transaminase, thereby raising GABA levels in the brain and promoting an inhibitory effect on neuronal firing. (36F)
​
Histone Deacetylase (HDAC) Inhibition: VPA, particularly against HDAC1, influences gene expression by modifying histone acetylation status—altering the accessibility of DNA for transcription. (36F)
Calcium Channel Modulation: While best known for blocking T-type calcium channels (key in absence seizures), VPA can also modulate L-type and N-type channels to a lesser degree. (36F)
​
​
​
​
Dilantin (Phenytoin)
Phenytoin is a medication used in the management and treatment of epilepsy, generalized tonic-clonic seizures, complex partial seizures, and status epilepticus. (37F)
Inhibition of Voltage-Gated Sodium Channels: Phenytoin binds preferentially to sodium channels in their inactivated state, slowing their return to the resting state and thus reducing repetitive neuronal firing, which stabilizes hyperexcitable neuronal membranes. (38F)
Minor Modulation of Calcium Channels: Some studies suggest phenytoin has a weak effect on high-voltage–activated calcium channels (e.g., L-type). (39F)
Reduces excessive glutamate release: Excessive glutamate release is associated with some seizure disorders, and glutamate is needed for normal neuronal signaling. (40F, 41F)
Side effects can include: rash, sedation, peripheral neuropathy, phenytoin encephalopathy, psychosis, locomotor dysfunction, hyperkinesia, megaloblastic anemia, decreased bone mineral content, Stevens-Johnson syndrome, toxic epidermal necrolysis, immunoglobulin A deficiency, gingival hyperplasia, dress syndrome (drug reaction accompanied by eosinophilia and systemic symptoms), cardiovascular collapse, hypotension, arrhythmias, hydantoin syndrome in newborns, purple glove syndrome, and hypertrichosis. (37F)
​
​
​
​
Other treatment options include
Dietary therapy with the ketogenic diet: The keto diet can increase extracellular adenosine levels, allowing more to bind to the adenosine A1 receptor. This reduces the amount of glutamate being released in the brain. (42F)
​
Vagus nerve stimulation; Vagus nerve stimulation (VNS) modifies plasticity in key brain areas by triggering the release of neuromodulators like acetylcholine and norepinephrine. This will enhance the brain's ability to reorganize neural circuits, particularly in regions associated with motor function, sensory processing, and emotional regulation. VNS can be useful in conditions like stroke, depression, and epilepsy when paired with targeted rehabilitation or training. (43F)
Complications of a VNS include: voice alteration, hoarseness, cough, tingling, dyspnea, vocal cord paralysis, implant site infection, left facial nerve paralysis, and Horner syndrome. (44F)
​
Epilepsy surgery (typically a corpus callostomy, which involves severing the band of nerve fibers that connect the two halves of the brain to prevent seizures from spreading). Complications can include: superficial hemosiderosis (anatomic hemispherectomy), progressive hydrocephalus (anatomic hemispherectomy), postoperative infarction from injury to the Sylvian vein sinus thrombosis, memory decline and anomic aphasia (temporal lobe resection), vasospasm and with contralateral superior quadrantanopia following the injury to Meyer's loop (amygdalohippocampectomy), disconnection syndrome (corpus callosotomy), hemiparesis and dysphagia (multiple subpial transections), and cough and hoarseness of voice (vagal nerve stimulation). (45F)
​
​
​
Epidiolex (CBD)
Epidiolex (CBD) is prescribed for children that are at least 1 year old. It is not known what happens to children under 1 that take Epidiolex. (46F) The doses are as follows (taken from the Epidiolex insert):
“The recommended starting dosage is 2.5 mg/kg by mouth twice daily (5 mg/kg/day). After one week, the dosage can be increased to a maintenance dosage of 5 mg/kg twice daily (10 mg/kg/day). Based on individual clinical response and tolerability, EPIDIOLEX can be increased up to a maximum recommended maintenance dosage of 10 mg/kg twice daily (20 mg/kg/day).“ 10 and 20 mg/kg/day dosages may lead to elevated liver enzymes. (46F)
Possible side effects in patients with Lennox-Gastaut syndrome or Dravet syndrome are: somnolence; decreased appetite; diarrhea; transaminase elevations; fatigue, malaise, and asthenia; rash; insomnia, sleep disorder, and poor quality sleep; and infections. (46F)
Possible side effects in patients with tuberous sclerosis complex are: diarrhea; transaminase elevations; decreased appetite; somnolence; pyrexia; and vomiting. (46F)
Personally, I cannot handle more than about 50mg of CBD every 4 hours. It makes me feel shaky, nauseated, and tired. Everyone will be different on how much they can take without side effects. Some of these pediatric doses can reach 10 mg/kg twice per day. A 20 kg child (44 Lbs) would be taking 200 mg twice per day. That high of a dose at a time could contribute to side effects. If the side effects are not tolerated well, then doctors should consider doing a lower dose more frequently, or try an entourage effect with CBD, CBC, CBN, and some terpenes like humulene, eucalyptol, and terpineol. Taking 3 cannabinoids and terpenes could possibly lower the amount of CBD needed, and reduce side effects. These combinations really need some targeted research.
Sources
​
36A. Kalinovskii AP, Utkina LL, Korolkova YV, Andreev YA. TRPV3 Ion Channel: From Gene to Pharmacology. Int J Mol Sci. 2023 May 11;24(10):8601. doi: 10.3390/ijms24108601. PMID: 37239947; PMCID: PMC10218142.
37A. Su W, Qiao X, Wang W, He S, Liang K, Hong X. TRPV3: Structure, Diseases and Modulators. Molecules. 2023 Jan 12;28(2):774. doi: 10.3390/molecules28020774. PMID: 36677834; PMCID: PMC9865980.
38A. Sherkheli MA, Benecke H, Doerner JF, Kletke O, Vogt-Eisele AK, Gisselmann G, Hatt H. Monoterpenoids induce agonist-specific desensitization of transient receptor potential vanilloid-3 (TRPV3) ion channels. J Pharm Pharm Sci. 2009;12(1):116-28. doi: 10.18433/j37c7k. PMID: 19470296.
39A. Vogt-Eisele AK, Weber K, Sherkheli MA, Vielhaber G, Panten J, Gisselmann G, Hatt H. Monoterpenoid agonists of TRPV3. Br J Pharmacol. 2007 Jun;151(4):530-40. doi: 10.1038/sj.bjp.0707245. Epub 2007 Apr 10. PMID: 17420775; PMCID: PMC2013969.
40A. GeneCards. (n.d.).TRPV3 Gene - GeneCards | The Human Gene Database. Retrieved 9/26/2024 from https://www.genecards.org/cgi-bin/carddisp.pl?gene=TRPV3&keywords=TRPV3
41A. Xu H, Delling M, Jun JC, Clapham DE. Oregano, thyme and clove-derived flavors and skin sensitizers activate specific TRP channels. Nat Neurosci. 2006 May;9(5):628-35. doi: 10.1038/nn1692. Epub 2006 Apr 16. PMID: 16617338.
42A. Murphy TV, Kanagarajah A, Toemoe S, Bertrand PP, Grayson TH, Britton FC, Leader L, Senadheera S, Sandow SL. TRPV3 expression and vasodilator function in isolated uterine radial arteries from non-pregnant and pregnant rats. Vascul Pharmacol. 2016 Aug;83:66-77. doi: 10.1016/j.vph.2016.04.004. Epub 2016 Apr 9. PMID: 27073026.
43A. Martin LS, Josset-Lamaugarny A, El Jammal T, Ducreux S, Chevalier FP, Fromy B. Aging is associated with impaired triggering of TRPV3-mediated cutaneous vasodilation: a crucial process for local heat exposure. Geroscience. 2024 Aug;46(4):3567-3580. doi: 10.1007/s11357-023-00981-5. Epub 2023 Oct 19. PMID: 37855862; PMCID: PMC11226586.
55A. GeneCards. (n.d.).TRPM8 Gene - GeneCards | The Human Gene Database. Retrieved 10/09/2024 from https://www.genecards.org/cgi-bin/carddisp.pl?gene=TRPM8
90A. Dhaliwal A, Gupta M. Physiology, Opioid Receptor. [Updated 2023 Jul 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK546642/
81B. National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 11601669, Cannabidivarin. Retrieved November 9, 2024 from https://pubchem.ncbi.nlm.nih.gov/compound/Cannabidivarin.
​
5C. Miyazawa M, Yamafuji C. Inhibition of acetylcholinesterase activity by bicyclic monoterpenoids. J Agric Food Chem. 2005 Mar 9;53(5):1765-8. doi: 10.1021/jf040019b. PMID: 15740071.
10C. Singh R, Sadiq NM. Cholinesterase Inhibitors. [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK544336/
35C. Ghossein N, Kang M, Lakhkar AD. Anticholinergic Medications. [Updated 2023 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK555893/
52C. Miyazawa M, Yamafuji C. Inhibition of acetylcholinesterase activity by bicyclic monoterpenoids. J Agric Food Chem. 2005 Mar 9;53(5):1765-8. doi: 10.1021/jf040019b. PMID: 15740071.
69C. Rao VS, Menezes AM, Viana GS. Effect of myrcene on nociception in mice. J Pharm Pharmacol. 1990 Dec;42(12):877-8. doi: 10.1111/j.2042-7158.1990.tb07046.x. PMID: 1983154.
6D. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The Clinical Translation of α-humulene - A Scoping Review. Planta Med. 2024 Aug;90(9):664-674. doi: 10.1055/a-2307-8183. Epub 2024 Apr 16. PMID: 38626911; PMCID: PMC11254484.
11D. Dos Santos Negreiros P, da Costa DS, da Silva VG, de Carvalho Lima IB, Nunes DB, de Melo Sousa FB, de Souza Lopes Araújo T, Medeiros JVR, Dos Santos RF, de Cássia Meneses Oliveira R. Antidiarrheal activity of α-terpineol in mice. Biomed Pharmacother. 2019 Feb;110:631-640. doi: 10.1016/j.biopha.2018.11.131. Epub 2018 Dec 9. PMID: 30540974.
33D. Takaishi M, Fujita F, Uchida K, Yamamoto S, Sawada Shimizu M, Hatai Uotsu C, Shimizu M, Tominaga M. 1,8-cineole, a TRPM8 agonist, is a novel natural antagonist of human TRPA1. Mol Pain. 2012 Nov 29;8:86. doi: 10.1186/1744-8069-8-86. PMID: 23192000; PMCID: PMC3567430.
37E. Hung NH, Quan PM, Satyal P, Dai DN, Hoa VV, Huy NG, Giang LD, Ha NT, Huong LT, Hien VT, Setzer WN. Acetylcholinesterase Inhibitory Activities of Essential Oils from Vietnamese Traditional Medicinal Plants. Molecules. 2022 Oct 20;27(20):7092. doi: 10.3390/molecules27207092. PMID: 36296686; PMCID: PMC9610647.
​
13F. Kollipara R, Langille E, Tobin C, French CR. Phytocannabinoids Reduce Seizures in Larval Zebrafish and Affect Endocannabinoid Gene Expression. Biomolecules. 2023 Sep 16;13(9):1398. doi: 10.3390/biom13091398. PMID: 37759798; PMCID: PMC10526363.
14F. Benson MJ, Anderson LL, Low IK, Luo JL, Kevin RC, Zhou C, McGregor IS, Arnold JC. Evaluation of the Possible Anticonvulsant Effect of Δ9-Tetrahydrocannabinolic Acid in Murine Seizure Models. Cannabis Cannabinoid Res. 2022 Feb;7(1):46-57. doi: 10.1089/can.2020.0073. Epub 2020 Sep 9. PMID: 33998858; PMCID: PMC8864425.
15F. Moyaert P, Beun S, Achten E, Clement P. Effect of Acetylcholinesterase Inhibitors on Cerebral Perfusion and Cognition: A Systematic Review. J Alzheimers Dis. 2023;93(4):1211-1221. doi: 10.3233/JAD-221125. PMID: 37182871; PMCID: PMC10357189.
16F. Capilupi MJ, Kerath SM, Becker LB. Vagus Nerve Stimulation and the Cardiovascular System. Cold Spring Harb Perspect Med. 2020 Feb 3;10(2):a034173. doi: 10.1101/cshperspect.a034173. PMID: 31109966; PMCID: PMC6996447.
17F. Khayat MT, Nayeem MA. The Role of Adenosine A2A Receptor, CYP450s, and PPARs in the Regulation of Vascular Tone. Biomed Res Int. 2017;2017:1720920. doi: 10.1155/2017/1720920. Epub 2017 Aug 13. PMID: 28884118; PMCID: PMC5572598.
18F. Shen HY, Baer SB, Gesese R, Cook JM, Weltha L, Coffman SQ, Wu J, Chen JF, Gao M, Ji T. Adenosine-A2A Receptor Signaling Plays a Crucial Role in Sudden Unexpected Death in Epilepsy. Front Pharmacol. 2022 Jun 9;13:910535. doi: 10.3389/fphar.2022.910535. PMID: 35754505; PMCID: PMC9218562.
19F. Brown CM, Sanya EO, Hilz MJ. Effect of cold face stimulation on cerebral blood flow in humans. Brain Res Bull. 2003 Jun 30;61(1):81-6. doi: 10.1016/s0361-9230(03)00065-0. PMID: 12788210.
20F. Culić V, Eterović D, Mirić D, Giunio L, Lukin A, Fabijanić D. Triggering of ventricular tachycardia by meteorologic and emotional stress: protective effect of beta-blockers and anxiolytics in men and elderly. Am J Epidemiol. 2004 Dec 1;160(11):1047-58. doi: 10.1093/aje/kwh335. PMID: 15561984.
21F. Nguyen JL, Link MS, Luttmann-Gibson H, Laden F, Schwartz J, Wessler BS, Mittleman MA, Gold DR, Dockery DW. Drier air, lower temperatures, and triggering of paroxysmal atrial fibrillation. Epidemiology. 2015 May;26(3):374-80. doi: 10.1097/EDE.0000000000000284. PMID: 25756220; PMCID: PMC4502955.
22F. Zanos P, Brown KA, Georgiou P, Yuan P, Zarate CA Jr, Thompson SM, Gould TD. NMDA Receptor Activation-Dependent Antidepressant-Relevant Behavioral and Synaptic Actions of Ketamine. J Neurosci. 2023 Feb 8;43(6):1038-1050. doi: 10.1523/JNEUROSCI.1316-22.2022. Epub 2023 Jan 3. PMID: 36596696; PMCID: PMC9908316.
23F. Alkhachroum A, Der-Nigoghossian CA, Mathews E, Massad N, Letchinger R, Doyle K, Chiu WT, Kromm J, Rubinos C, Velazquez A, Roh D, Agarwal S, Park S, Connolly ES, Claassen J. Ketamine to treat super-refractory status epilepticus. Neurology. 2020 Oct 20;95(16):e2286-e2294. doi: 10.1212/WNL.0000000000010611. Epub 2020 Sep 1. PMID: 32873691; PMCID: PMC7713785.
24F. Jewett BE, Thapa B. Physiology, NMDA Receptor. [Updated 2022 Dec 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519495/
25F. Mayo Clinic. Antihistamine, decongestant, and anticholinergic combination (oral route). March 31, 2024. Retrieved January 27, 2025 from https://www.mayoclinic.org/drugs-supplements/antihistamine-decongestant-and-anticholinergic-combination-oral-route/description/drg-20069979
26F. Sanabria V, Romariz S, Braga M, Foresti ML, Naffah-Mazzacoratti MDG, Mello LE, Longo BM. Anticholinergics: A potential option for preventing posttraumatic epilepsy. Front Neurosci. 2023 Feb 24;16:1100256. doi: 10.3389/fnins.2022.1100256. PMID: 36909741; PMCID: PMC9998514.
27F. Potschka H, Friderichs E, Löscher W. Anticonvulsant and proconvulsant effects of tramadol, its enantiomers and its M1 metabolite in the rat kindling model of epilepsy. Br J Pharmacol. 2000 Sep;131(2):203-12. doi: 10.1038/sj.bjp.0703562. PMID: 10991912; PMCID: PMC1572317.
28F. Johnson CD, Melanaphy D, Purse A, Stokesberry SA, Dickson P, Zholos AV. Transient receptor potential melastatin 8 channel involvement in the regulation of vascular tone. Am J Physiol Heart Circ Physiol. 2009 Jun;296(6):H1868-77. doi: 10.1152/ajpheart.01112.2008. Epub 2009 Apr 10. PMID: 19363131; PMCID: PMC2716108.
29F. National institute of neurological disorders and stroke. Lennox-Gastaut syndrome. ND. Retrieved January 31, 2025 from https://www.ninds.nih.gov/health-information/disorders/lennox-gastaut-syndrome
30F. Calhoun JD, Hawkins NA, Zachwieja NJ, Kearney JA. Cacna1g is a genetic modifier of epilepsy in a mouse model of Dravet syndrome. Epilepsia. 2017 Aug;58(8):e111-e115. doi: 10.1111/epi.13811. Epub 2017 May 28. PMID: 28556246; PMCID: PMC5554089.
31F. National institute for neurological disorders and stroke. Dravet syndrome. N.D. Retrieved January 27, 2025 from https://www.ninds.nih.gov/health-information/disorders/dravet-syndrome
32F. Riban V, Heulard I, Reversat L, Si Hocine H, Verleye M. Stiripentol inhibits spike-and-wave discharges in animal models of absence seizures: A new mechanism of action involving T-type calcium channels. Epilepsia. 2022 May;63(5):1200-1210. doi: 10.1111/epi.17201. Epub 2022 Mar 9. PMID: 35184274; PMCID: PMC9314114.
33F. Kumar A, Maini K, Kadian R. Levetiracetam. [Updated 2023 Dec 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499890/
34F. Lee CY, Chen CC, Liou HH. Levetiracetam inhibits glutamate transmission through presynaptic P/Q-type calcium channels on the granule cells of the dentate gyrus. Br J Pharmacol. 2009 Dec;158(7):1753-62. doi: 10.1111/j.1476-5381.2009.00463.x. PMID: 19888964; PMCID: PMC2801216.
35F. Jeyakumar, M., Guhan, V. N., Prabhakara Rao, K., Jayanthi Arulneyam, S., Sivaa, R., & Anil Kumar, M. (2014). Impact of Levetiracetam on Bone Health - A Descriptive Study. International Journal of Pharmaceutical Sciences Review and Research, 26(1), 152-154.
36F. Rahman M, Awosika AO, Nguyen H. Valproic Acid. [Updated 2024 Mar 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559112/
37F. Gupta M, Tripp J. Phenytoin. [Updated 2023 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551520/
38F. Zeng Z, Hill-Yardin EL, Williams D, O'Brien T, Serelis A, French CR. Effect of phenytoin on sodium conductances in rat hippocampal CA1 pyramidal neurons. J Neurophysiol. 2016 Oct 1;116(4):1924-1936. doi: 10.1152/jn.01060.2015. Epub 2016 Aug 3. PMID: 27489371; PMCID: PMC5144711.
39F. Twombly DA, Yoshii M, Narahashi T. Mechanisms of calcium channel block by phenytoin. J Pharmacol Exp Ther. 1988 Jul;246(1):189-95. PMID: 2455791.
40F. Wong PT, Teo WL. The effect of phenytoin on glutamate and GABA transport. Neurochem Res. 1986 Sep;11(9):1379-82. doi: 10.1007/BF00966131. PMID: 2946971.
41F. Barker-Haliski M, White HS. Glutamatergic Mechanisms Associated with Seizures and Epilepsy. Cold Spring Harb Perspect Med. 2015 Jun 22;5(8):a022863. doi: 10.1101/cshperspect.a022863. PMID: 26101204; PMCID: PMC4526718.
42F. Imdad K, Abualait T, Kanwal A, AlGhannam ZT, Bashir S, Farrukh A, Khattak SH, Albaradie R, Bashir S. The Metabolic Role of Ketogenic Diets in Treating Epilepsy. Nutrients. 2022 Nov 29;14(23):5074. doi: 10.3390/nu14235074. PMID: 36501104; PMCID: PMC9738161.
43F. Engineer, N. D., Kimberley, T. J., Prudente, C. N., Dawson, J., Tarver, B., & Hays, S. A. (2019). Targeted vagus nerve stimulation for rehabilitation after stroke. Frontiers in Neuroscience, 13, 280. https://doi.org/10.3389/fnins.2019.00280
44F. Mandalaneni K, Rayi A. Vagus Nerve Stimulator. [Updated 2023 Aug 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562175/
45F. Munakomi S, Das JM. Epilepsy Surgery. [Updated 2023 Aug 14]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562151/
46F. Jazz Pharmaceuticals, Inc. (2024). EPIDIOLEX (cannabidiol) [Package insert]. Retrieved January 20, 2025 from https://pp.jazzpharma.com/pi/epidiolex.en.USPI.pdf
47F. Campbell N, Boustani M, Limbil T, Ott C, Fox C, Maidment I, Schubert CC, Munger S, Fick D, Miller D, Gulati R. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 2009;4:225-33. doi: 10.2147/cia.s5358. Epub 2009 Jun 9. PMID: 19554093; PMCID: PMC2697587.
48F. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Anticholinergic Agents. [Updated 2017 Jul 7]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548287/
49F. Pan, Y., Thapa, D., Baldissera, L. et al. Relevance of TRPA1 and TRPM8 channels as vascular sensors of cold in the cutaneous microvasculature. Pflugers Arch - Eur J Physiol 470, 779–786 (2018). https://doi.org/10.1007/s00424-017-2085-9
50F. Kim JH, Lee CK, Yu SH, Min BD, Chung CE, Kim DC. Ketamine-induced generalized convulsive seizure during procedural sedation. Arch Craniofac Surg. 2021 Apr;22(2):119-121. doi: 10.7181/acfs.2021.00094. Epub 2021 Apr 20. PMID: 33957739; PMCID: PMC8107456.
51F. Perucca E. Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last? J Epilepsy Res. 2017 Dec 31;7(2):61-76. doi: 10.14581/jer.17012. PMID: 29344464; PMCID: PMC5767492.